Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas.
Gerhartz
H H
HH
Medical Dept III, Klinikum Grosshadern, Munich University, Germany.
Engelhard
M
M
Brittinger
G
G
Schlimok
G
G
Thiel
E
E
Huber
C
C
Emmerich
B
B
Schadek
C
C
Brandmaier
R
R
Stern
A C
AC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000627:therapeutic use; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D011994:Recombinant Proteins; D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D011241:Prednisone